Azithromycin in the treatment of mucosal leishmaniasis

Authors

  • Mario León Silva-Vergara Faculdade de Medicina do Triângulo Mineiro; Departamento de Clínica Médica
  • Luciana de Almeida Silva Faculdade de Medicina do Triângulo Mineiro; Departamento de Clínica Médica
  • Frederico Ricardo Zago Maneira Faculdade de Medicina do Triângulo Mineiro; Departamento de Clínica Médica
  • Achilles Gustavo da Silva Faculdade de Medicina do Triângulo Mineiro; Departamento de Clínica Médica
  • Aluízio Prata Faculdade de Medicina do Triângulo Mineiro; Departamento de Clínica Médica

Keywords:

Mucosal leishmaniasis, Azithromycin, Chronic cardiopathy

Abstract

This report describes three elderly patients with mucosal form of American tegumentary leishmaniasis associated with chronic cardiopathy. Due to the known toxicity of classical drugs with activity against Leishmania sp., the patients received three oral courses of azithromycin therapy in single 500 mg daily dose during ten days, every other month. All lesions healed after the third series. One of the patients relapsed and a new series of azithromycin was prescribed. Azithromycin may be an alternative drug for the treatment of leishmaniasis in special situations due to its optimal mucosal and intraphagocyte concentration, single daily posology, high tolerance and oral administration. The mechanism of this drug on Leishmania sp. is unknown at present.

Downloads

Download data is not yet available.

Downloads

Published

2004-06-01

Issue

Vol. 46 No. 3 (2004)

Section

Case Report

How to Cite

Silva-Vergara, M. L., Silva, L. de A., Maneira, F. R. Z., Silva, A. G. da, & Prata, A. (2004). Azithromycin in the treatment of mucosal leishmaniasis . Revista Do Instituto De Medicina Tropical De São Paulo, 46(3), 175-177. https://www.revistas.usp.br/rimtsp/article/view/30814